<DOC>
	<DOC>NCT03091855</DOC>
	<brief_summary>Patients will be screened at Intermountain Medical Center and at Intermountain affiliated anticoagulation clinics in the Salt Lake City region. Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.</brief_summary>
	<brief_title>PLUG Dementia Trial</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>1. Male or female &gt;65 years of age 2. Atrial fibrillation documented by electrocardiogram, ambulatory event monitor, or telemetry within 6 months of enrollment 3. Moderate risk of thromboembolism based upon a CHADS2 score or CHADS2 Vasc score of â‰¥2. 4. Recipient of a left atrial appendage closure system within 3 months of study enrollment 5. Ability to complete a minimental status evaluation 6. Ability to independently comprehend and complete a quality of life and dementia questionnaires. 7. Ability to provide informed consent for study participation 8. Willing and able to comply with the prescribed followup tests and schedule of evaluations. 1. History of any form of dementia 2. A life expectancy less than 24 months 3. Inability to comply with the followup schedule 4. An upper age limit not to be used if participation inclusion criteria are met. 5. Participation in any other clinical trials involving an investigational or marketed drug within 30 days prior to entry in this study; 6. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial; and 7. The Principal Investigator(s) determine(s) that the subject is not eligible for participation in this research study.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>